Loading
Early Onset Alzheimer Disease / ALN-APP · Phase 1 Trial
ClinicalTrials.gov · August 12, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 1 clinical trial registration for ALN-APP, a novel intrathecal agent targeting amyloid precursor protein in early-onset Alzheimer disease. No results have been posted in the registry record; the study is currently recruiting and designed to evaluate safety, tolerability, pharmacodynamics, and pharmacokinetics over up to 42 months. Clinicians and researchers should await publication of completed trial data before drawing any conclusions about efficacy or safety profile.
Phase 1, Interventional, Randomized, Parallel, Triple masking, Treatment purpose. Early-Onset Alzheimer Disease; age from 18 Years. Intervention: Part A: ALN-APP; Part B:. Compared with: Part A: Placebo — Placebo Comparator. n = 60. 8 sites across 4 countries.
This is a Phase 1 clinical trial registration for ALN-APP, a novel intrathecal agent targeting amyloid precursor protein in early-onset Alzheimer disease. No results have been posted in the registry record; the study is currently recruiting and designed to evaluate safety, tolerability, pharmacodynamics, and pharmacokinetics over up to 42 months. Clinicians and researchers should await publication of completed trial data before drawing any conclusions about efficacy or safety profile.
Registry record only; no efficacy, safety, or pharmacokinetic results have been posted or reported. Phase 1 design limits inference to safety and tolerability; efficacy data will not be available until later-phase trials.
This registry record provides no clinical impact at present. Clinicians should monitor for publication of safety and tolerability results from this Phase 1 trial, which will inform whether progression to later-phase efficacy studies is warranted.
Phase 1 study registration with no reported results; evaluates safety and tolerability of a novel intrathecal agent in early-onset Alzheimer disease, requiring confirmation in later-phase trials.
As stated by the source record.
Quoted from the source exactly as published.
This registry record provides no clinical impact at present. Clinicians should monitor for publication of safety and tolerability results from this Phase 1 trial, which will inform whether progression to later-phase efficacy studies is warranted.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT05231785). This is a study registration, not published results. Lead sponsor: Alnylam Pharmaceuticals. Recruitment status: RECRUITING. Phase: PHASE1. Study type: INTERVENTIONAL. Enrollment: 60 participants (ESTIMATED). Conditions: Early-Onset Alzheimer Disease. Interventions: DRUG: ALN-APP; DRUG: Placebo. Primary outcome measures: Part A: Frequency of Adverse Events , Up to 12 months; Part B: Frequency of Adverse Events , Up to 42 months. Brief summary: The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of a single dose and multiple doses of ALN-APP administered by intrathecal (IT) injection in adult patients with early-onset Alzheimer's Disease (EOAD). Maximum treatment duration for Part A: single dose. Maximum treatment duration for Part B: 12 months.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.